Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

Howard Safran, David Iannitti, Ramesk K Ramanathan, Jonathan D. Schwartz, Margaret Steinhoff, Chris Nauman, Paul Hesketh, Ritesh Rathore, Robert Wolf, Umadevi Tantravahi, Marilyn Hughes, Chris Maia, Terry Pasquariello, Lisa Goldstein, Thomas King, James Y. Tsai, Teresa Kennedy

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Purpose: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. Methods and Materials: Patients with metastatic pancreatic cancer with 2+/3+ HER-2/neu expression by immunohistochemistry were eligible. Patients received gemcitabine, 1 g/m2/week, for 7 of 8 weeks followed by 3 of every 4 weeks, and Herceptin, 4 mg/kg loading dose, followed by 2 mg/kg/week. Results: Screening logs demonstrated the rate of HER-2/neu overexpression was 16%. Thirty-four patients were enrolled. Thirty patients (88%) had pancreatic cancers with 2+ overexpression and 4 patients (12%) had 3+ overexpression. Toxicity was similar to gemcitabine alone. Confirmed partial responses were observed in 2 of 32 patients (6%). Thirteen of 32 patients (41%) had either a partial response or a > 50% reduction in CA 19-9. The median survival for all 34 patients was 7 months, and the 1-year survival was 19%. Conclusion: The response rate of Herceptin and gemcitabine is similar to gemcitabine alone. The 7-month median survival in patients with metastatic pancreatic cancer suggests there may be a modest benefit for some patients. Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)706-712
Number of pages7
JournalCancer Investigation
Volume22
Issue number5
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
erbB-2 Genes
Survival
Trastuzumab

Keywords

  • HER-2/neu
  • Herceptin
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Safran, H., Iannitti, D., Ramanathan, R. K., Schwartz, J. D., Steinhoff, M., Nauman, C., ... Kennedy, T. (2004). Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation, 22(5), 706-712. https://doi.org/10.1081/CNV-200032974

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. / Safran, Howard; Iannitti, David; Ramanathan, Ramesk K; Schwartz, Jonathan D.; Steinhoff, Margaret; Nauman, Chris; Hesketh, Paul; Rathore, Ritesh; Wolf, Robert; Tantravahi, Umadevi; Hughes, Marilyn; Maia, Chris; Pasquariello, Terry; Goldstein, Lisa; King, Thomas; Tsai, James Y.; Kennedy, Teresa.

In: Cancer Investigation, Vol. 22, No. 5, 2004, p. 706-712.

Research output: Contribution to journalArticle

Safran, H, Iannitti, D, Ramanathan, RK, Schwartz, JD, Steinhoff, M, Nauman, C, Hesketh, P, Rathore, R, Wolf, R, Tantravahi, U, Hughes, M, Maia, C, Pasquariello, T, Goldstein, L, King, T, Tsai, JY & Kennedy, T 2004, 'Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu', Cancer Investigation, vol. 22, no. 5, pp. 706-712. https://doi.org/10.1081/CNV-200032974
Safran, Howard ; Iannitti, David ; Ramanathan, Ramesk K ; Schwartz, Jonathan D. ; Steinhoff, Margaret ; Nauman, Chris ; Hesketh, Paul ; Rathore, Ritesh ; Wolf, Robert ; Tantravahi, Umadevi ; Hughes, Marilyn ; Maia, Chris ; Pasquariello, Terry ; Goldstein, Lisa ; King, Thomas ; Tsai, James Y. ; Kennedy, Teresa. / Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. In: Cancer Investigation. 2004 ; Vol. 22, No. 5. pp. 706-712.
@article{985f241b3818440282a4113636c4a1e2,
title = "Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu",
abstract = "Purpose: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. Methods and Materials: Patients with metastatic pancreatic cancer with 2+/3+ HER-2/neu expression by immunohistochemistry were eligible. Patients received gemcitabine, 1 g/m2/week, for 7 of 8 weeks followed by 3 of every 4 weeks, and Herceptin, 4 mg/kg loading dose, followed by 2 mg/kg/week. Results: Screening logs demonstrated the rate of HER-2/neu overexpression was 16{\%}. Thirty-four patients were enrolled. Thirty patients (88{\%}) had pancreatic cancers with 2+ overexpression and 4 patients (12{\%}) had 3+ overexpression. Toxicity was similar to gemcitabine alone. Confirmed partial responses were observed in 2 of 32 patients (6{\%}). Thirteen of 32 patients (41{\%}) had either a partial response or a > 50{\%} reduction in CA 19-9. The median survival for all 34 patients was 7 months, and the 1-year survival was 19{\%}. Conclusion: The response rate of Herceptin and gemcitabine is similar to gemcitabine alone. The 7-month median survival in patients with metastatic pancreatic cancer suggests there may be a modest benefit for some patients. Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer.",
keywords = "HER-2/neu, Herceptin, Pancreatic adenocarcinoma",
author = "Howard Safran and David Iannitti and Ramanathan, {Ramesk K} and Schwartz, {Jonathan D.} and Margaret Steinhoff and Chris Nauman and Paul Hesketh and Ritesh Rathore and Robert Wolf and Umadevi Tantravahi and Marilyn Hughes and Chris Maia and Terry Pasquariello and Lisa Goldstein and Thomas King and Tsai, {James Y.} and Teresa Kennedy",
year = "2004",
doi = "10.1081/CNV-200032974",
language = "English (US)",
volume = "22",
pages = "706--712",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

AU - Safran, Howard

AU - Iannitti, David

AU - Ramanathan, Ramesk K

AU - Schwartz, Jonathan D.

AU - Steinhoff, Margaret

AU - Nauman, Chris

AU - Hesketh, Paul

AU - Rathore, Ritesh

AU - Wolf, Robert

AU - Tantravahi, Umadevi

AU - Hughes, Marilyn

AU - Maia, Chris

AU - Pasquariello, Terry

AU - Goldstein, Lisa

AU - King, Thomas

AU - Tsai, James Y.

AU - Kennedy, Teresa

PY - 2004

Y1 - 2004

N2 - Purpose: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. Methods and Materials: Patients with metastatic pancreatic cancer with 2+/3+ HER-2/neu expression by immunohistochemistry were eligible. Patients received gemcitabine, 1 g/m2/week, for 7 of 8 weeks followed by 3 of every 4 weeks, and Herceptin, 4 mg/kg loading dose, followed by 2 mg/kg/week. Results: Screening logs demonstrated the rate of HER-2/neu overexpression was 16%. Thirty-four patients were enrolled. Thirty patients (88%) had pancreatic cancers with 2+ overexpression and 4 patients (12%) had 3+ overexpression. Toxicity was similar to gemcitabine alone. Confirmed partial responses were observed in 2 of 32 patients (6%). Thirteen of 32 patients (41%) had either a partial response or a > 50% reduction in CA 19-9. The median survival for all 34 patients was 7 months, and the 1-year survival was 19%. Conclusion: The response rate of Herceptin and gemcitabine is similar to gemcitabine alone. The 7-month median survival in patients with metastatic pancreatic cancer suggests there may be a modest benefit for some patients. Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer.

AB - Purpose: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. Methods and Materials: Patients with metastatic pancreatic cancer with 2+/3+ HER-2/neu expression by immunohistochemistry were eligible. Patients received gemcitabine, 1 g/m2/week, for 7 of 8 weeks followed by 3 of every 4 weeks, and Herceptin, 4 mg/kg loading dose, followed by 2 mg/kg/week. Results: Screening logs demonstrated the rate of HER-2/neu overexpression was 16%. Thirty-four patients were enrolled. Thirty patients (88%) had pancreatic cancers with 2+ overexpression and 4 patients (12%) had 3+ overexpression. Toxicity was similar to gemcitabine alone. Confirmed partial responses were observed in 2 of 32 patients (6%). Thirteen of 32 patients (41%) had either a partial response or a > 50% reduction in CA 19-9. The median survival for all 34 patients was 7 months, and the 1-year survival was 19%. Conclusion: The response rate of Herceptin and gemcitabine is similar to gemcitabine alone. The 7-month median survival in patients with metastatic pancreatic cancer suggests there may be a modest benefit for some patients. Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer.

KW - HER-2/neu

KW - Herceptin

KW - Pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=19944429073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429073&partnerID=8YFLogxK

U2 - 10.1081/CNV-200032974

DO - 10.1081/CNV-200032974

M3 - Article

VL - 22

SP - 706

EP - 712

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5

ER -